The Future of Drug Trials - Interview

Posted:
29
September 2006

BBC journalist Graham Easton investigates the future of drug trials following the events of trial TGN1412.The BBC interviewer talks to Professor Gordon Duff (Commission on Human Medicines), Professor Andre Mclean (Imperial College London), Dr Jörg Täubel (Richmond Pharmacology), Professor Terry Hamblin (University of Southampton), Dr Ganesh Suntharalingam (Northwick Park Hospital), Professor Deborah Saltman (BioMedical Central), Dr Elaine Godfrey (MHRA), and Dr Mark Lewis (Strategic Health Authority), to get their opinion leading analysis of the event and the future of drug trials, covering:

  • What can be learnt and changed from the incident?
  • Should all first in man trials be conducted in a Hospital setting?
  • Regulatory issues

Click here to read the transcript

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more